These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 18060020)

  • 1. Nonviral delivery of synthetic siRNAs in vivo.
    Akhtar S; Benter IF
    J Clin Invest; 2007 Dec; 117(12):3623-32. PubMed ID: 18060020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics.
    Akhtar S
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1347-62. PubMed ID: 20929276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic face of RNAi: in vivo challenges.
    Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
    Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA: Mechanism of action, challenges, and therapeutic approaches.
    Alshaer W; Zureigat H; Al Karaki A; Al-Kadash A; Gharaibeh L; Hatmal MM; Aljabali AAA; Awidi A
    Eur J Pharmacol; 2021 Aug; 905():174178. PubMed ID: 34044011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycation-based nanoparticle delivery for improved RNA interference therapeutics.
    Howard KA; Kjems J
    Expert Opin Biol Ther; 2007 Dec; 7(12):1811-22. PubMed ID: 18034647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knocking down barriers: advances in siRNA delivery.
    Whitehead KA; Langer R; Anderson DG
    Nat Rev Drug Discov; 2009 Feb; 8(2):129-38. PubMed ID: 19180106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research progress on siRNA delivery with nonviral carriers.
    Gao Y; Liu XL; Li XR
    Int J Nanomedicine; 2011; 6():1017-25. PubMed ID: 21720513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.
    de Fougerolles A; Manoharan M; Meyers R; Vornlocher HP
    Methods Enzymol; 2005; 392():278-96. PubMed ID: 15644187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomaterials in siRNA Delivery: A Comprehensive Review.
    Ho W; Zhang XQ; Xu X
    Adv Healthc Mater; 2016 Nov; 5(21):2715-2731. PubMed ID: 27700013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of short interfering RNAs--strategies for in vivo delivery.
    Wullner U; Neef I; Tur MK; Barth S
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):1-8. PubMed ID: 19149683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design and exogenous delivery of siRNA for post-transcriptional gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Sohail M; Akhtar S
    J Drug Target; 2004 Jul; 12(6):315-40. PubMed ID: 15545082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi-based drug discovery and its application to therapeutics.
    Hokaiwado N; Takeshita F; Banas A; Ochiya T
    IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress toward in vivo use of siRNAs-II.
    Rettig GR; Behlke MA
    Mol Ther; 2012 Mar; 20(3):483-512. PubMed ID: 22186795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in chemically modified siRNAs.
    Gaglione M; Messere A
    Mini Rev Med Chem; 2010 Jun; 10(7):578-95. PubMed ID: 20500149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery strategies for siRNA-mediated gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Akhtar S
    Curr Drug Deliv; 2006 Apr; 3(2):147-5. PubMed ID: 16611001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient siRNA delivery with non-viral polymeric vehicles.
    Kim WJ; Kim SW
    Pharm Res; 2009 Mar; 26(3):657-66. PubMed ID: 19015957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.